San Diego, CA -- (SBWire) -- 06/30/2017 --An investigation was announced for investors in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) was announced over potential breaches of fiduciary duties by certain directors at RXi Pharmaceuticals.
Investors who purchased shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain RXi Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Marlborough, MA based RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. RXi Pharmaceuticals Corp (NASDAQ:RXII) shares declined from $2.90 per share in June 2016 to $0.51 per share in May 2017.
On June 16, 2017, NASDAQ:RXII shares closed at $0.55 per share.
Those who purchased shares of RXi Pharmaceuticals Corp have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
RXi Pharmaceuticals Corp (NASDAQ:RXII) Investor Investigation Concerning Potential Wrongdoing
An investigation on behalf of investors in NASDAQ:RXII shares over potential wrongdoing at RXi Pharmaceuticals was announced and NASDAQ:RXII stockholders should contact the Shareholders Foundation.